PTA · Class II · 21 CFR 866.5950

FDA Product Code PTA: Genetic Variant Detection And Health Risk Assessment System

A Qualitative In Vitro Molecular Test That Detects Variants In Genomic Dna Isolated From Human Specimens. This Assessment System Provides Users With A Genetic Health Risk Assessment Of Developing A Disease And Is Intended To Inform Users Of Lifestyle Choices And/or Encourage Conversations With A Healthcare Professional. This Assessment System Is For Over-the-counter Use. This Device Does Not Determine The Person’s Overall Risk Of Developing A Disease.

Leading manufacturers include Targeted Genomics, LLC and Progenika Biopharma S.A., A Grifols Company.

5
Total
4
Cleared
297d
Avg days
2017
Since
Stable submission activity - 1 submissions in the last 2 years
Review times improving: avg 230d recently vs 314d historically

FDA 510(k) Cleared Genetic Variant Detection And Health Risk Assessment System Devices (Product Code PTA)

5 devices
1–5 of 5

About Product Code PTA - Regulatory Context

510(k) Submission Activity

5 total 510(k) submissions under product code PTA since 2017, with 4 receiving FDA clearance (average review time: 297 days).

Submission volume has remained relatively stable over the observed period, with 1 submissions in the last 24 months.

FDA Review Time

Recent submissions under PTA have taken an average of 230 days to reach a decision - down from 314 days historically, suggesting improved FDA processing for this classification.

PTA devices are reviewed by the Immunology panel. Browse all Immunology devices →